Výsledky vyhledávání - "Robert B. Bettis"

Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Autor: Craig LaForce, Choy Y. Man, Laila Kudule, Frederick W. Henderson, Frank C. Hampel, Margaret Tisdale, Julia Harris, Alison Webster, Janet E. McElhaney, Robert B. Bettis, Philip Yates

Publikováno v: Clinical Therapeutics. 29:1579-1590

Influenza can cause significant morbidity and mortality in subjects at high risk for complications, including the elderly (ageor=65 years) and those with chronic respiratory, cardiovascular, or metabolic conditions. Effective prophylaxis can signific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8d53afb04e05fb75d9107022e7a27bc
https://doi.org/10.1016/j.clinthera.2007.08.023

Zobrazit plný text záznamu

Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women

Autor: Steven F. Kowalsky, Robert B. Bettis, Deborah A. Church, Kathryn Manning, Kamal Hamed, Ernie Riffer, Daniel Haverstock, Dan C. Henry

Publikováno v: Clinical Therapeutics. 24:2088-2104

Background: Trimethoprim/sulfamethoxazole (TMP/SMX) is currently the first choice for empiric therapy of acute uncomplicated urinary tract infection (UTI) in women. In areas where resistance to TMP/SMX is known to be high, ciprofloxacin and other flu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9364795f61db3e5ed5e27bf0e1e9bef
https://doi.org/10.1016/s0149-2918(02)80099-6

Zobrazit plný text záznamu

A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis

Autor: Nicole F. Li, Lawrence Sher, Phillip F. Pierce, Michael A. McAdoo, Mark A. Turner, Robert B. Bettis

Publikováno v: Clinical Therapeutics. 24:269-281

Background: Treatment guidelines for acute bacterial sinusitis recommend 10 to 14 days of therapy with amoxicillin/clavulanate, high-dose amoxicillin, cefpodoxime, cefuroxime, or a newer fluoroquinolone. Objective: This study compared the clinical ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8108e3c1ceb9ea96d51f45d44c1c5c9
https://doi.org/10.1016/s0149-2918(02)85023-8

Zobrazit plný text záznamu

Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis

Autor: Charles M. Fogarty, Robert B. Bettis, Timothy J. Griffin, Kenneth J. Tack, Constance H. Keyserling, Mary Anne Nemeth

Publikováno v: Journal of Antimicrobial Chemotherapy. 45:851-858

Patients with acute exacerbations of chronic bronchitis were treated with cefdinir 300 mg bd for 5 days or cefprozil 500 mg bd for 10 days in a prospective, randomized, double-blind, multicentre study. Of the 548 patients enrolled, 281 (51%) were eva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1262610f3501f091923a0ecf92b8372a
https://doi.org/10.1093/jac/45.6.851

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání